Return to content in this issue

Successful Desensitization to Oral Dasatinib in Immediate Hypersensitivity Reaction

Ruano-Zaragoza M^1,2,3*, Torrent-Rodríguez A^4*, Araujo-Sanchez G^1,2,3, Ribó P¹, Loli-Ausejo D¹, Solis K¹, Sánchez-Fernández MC¹, Bolaños J⁵, Bolós U⁵, López C⁴, Ruiz S⁴, Pascal M^3,5, Bartra J^1,2,3, Muñoz-Cano R<sup>1,2,3

1</sup>Allergy Department, Hospital Clínic, Barcelona, Spain
²Clinical & Experimental Respiratory Immunoallergy, Institut Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
³RETIC Asma, Reacciones Adversas y Alergia (ARADyAL) and RICORS Red de Enfermedades Inflamatorias (REI), Madrid, Spain
⁴Pharmacy Department, Hospital Clínic, Barcelona, Spain
⁵Immunology Department, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Barcelona, Spain
^*These authors contributed equally to this work and should be considered joint first authors.

J Investig Allergol Clin Immunol 2024; Vol 34(4) : 274-276
doi: 10.18176/jiaci.0985

• Abstract
• Supplemental Materials

Key words: Oral desensitization, Dasatinib, Drug allergy, Tyrosine kinase inhibitors, Basophil activation test

	Title	Type	Size
	doi10.18176_jiaci.0985_supplemental-materials-figure_1.pdf	pdf	188.06 Kb
	doi10.18176_jiaci.0985_supplemental-materials-table_1.pdf	pdf	89.33 Kb